Articles tagged with Cytotoxic T Cells
A new study reveals that helper T cells play a vital role in cancer immunotherapy, and activating them alongside killer T cells can lead to more effective treatments. The research suggests that combining immune checkpoint therapy with vaccines targeting both types of T cells may be the key to improving treatment outcomes for patients
Researchers found that disrupting the PTPN2 gene boosts anti-tumor immunity, enabling cancer clearance in animal models. Deleting the gene stimulates production and fitness of T-killer cells, which are critical in warding off tumors.
New research reveals creatine powers CD8 T cells' fight against cancer by storing and distributing energy. Creatine supplementation enhances existing immunotherapies, including PD-1/PD-L1 blockade therapy, leading to significant tumor eradication rates.
Researchers developed a new gene editing system that simultaneously suppresses proteins inhibiting the immune system in lymphoma cells and activates cytotoxic T lymphocytes. The technology, based on improved CRISPR gene editing, shows promise for treating various diseases including cancer, autoimmune, and inflammatory conditions.
A new study reveals that CD8+ cytotoxic T lymphocytes can penetrate and destroy large target masses, such as those associated with Toxoplasma gondii infection. This ability may also be effective against solid cancers.
A Stanford University School of Medicine study found that immune cells called killer T cells infiltrate neurogenic niches in the aging brain, secreting a substance that chokes off new nerve cell production. This breakthrough could lead to progress in treating age-related brain deterioration and finding treatments to reverse it.
A study published in Nature Ecology & Evolution found that differences in vertebrae numbers are most extreme in mammals that don't rely on running and leaping. The research suggests that a particular type of locomotor behavior, such as suspensory locomotion, is associated with increases in variation in vertebrae count across mammals.
Researchers at UVA School of Medicine discovered a defect in killer T cells that makes them ineffective against cancer. Repairing this defect could make the cells better cancer killers.
A powerful molecule, HLA-G dimer, helps protect transplanted organs from rejection by quietening two other immune molecules. The study provides more evidence that this molecule should be an effective therapy for protecting transplanted organs, and its potential to improve outcomes in organ transplant patients.
Scientists warn that rising temperatures could make some species sterile and lead to earlier extinction than thought. The Thermal Fertility Limit, a new measure of how organisms function at extreme temperatures, may help predict which species are most vulnerable.
Researchers have identified a cellular mechanism by which cold tumors can be made susceptible to immunotherapy. The study found that inducing UCP2 expression in tumor cells prompts an anti-cancer immune response, drawing killer T cells and conventional type 1 dendritic cells into the microenvironment.
Researchers have developed a stable and pure form of epsilon iron carbide that generates almost no CO2 during the Fischer-Tropsch process. This breakthrough could reduce operating costs by up to 25 million euros per year and facilitate more efficient carbon capture and utilization.
Researchers identified cytotoxic T cell responses to Ebola-specific proteins in 26 Sierra Leonean survivors, suggesting a vaccine targeting both viral nucleoprotein and glycoprotein could elicit cell-mediated immunity. The study provides insights into the immune response of Ebola survivors and potential strategies for vaccine development.
A new Scripps Research study found that nearly all Ebola survivors had killer T cells responding to the nucleoprotein, while only a minority responded to the glycoprotein. This discovery suggests a more effective vaccine strategy by targeting both proteins.
Researchers developed a novel vaccine strategy that blocks the death of tumor-specific cytotoxic T cells, leading to improved antitumor efficacy in mice. The approach involves increasing the amount of time interleukin 2 (IL2) stays in the body, enhancing the activation and survival of these immune cells.
Scientists at Helmholtz Zentrum München have identified 16 virus structures that can be attacked by killer T cells, which could lead to new therapies for immunocompromised individuals and patients with autoimmune diseases. The researchers discovered these targets using an algorithm and verified them in a large group of patients.
A new study reveals that non-specific bystander T cells can counteract type 1 diabetes by limiting access to beta cells and interfering with inflammatory signals. This challenge to the traditional notion of regulatory T cells' anti-inflammatory effects opens up new avenues for treatment.
Researchers at La Jolla Institute for Allergy and Immunology identified a hitherto unknown precursor for a poorly understood subgroup of killer T cells. Single-cell transcriptome analysis revealed an unprecedented level of heterogeneity among immune cells, upending the traditional view of immune cells as unvarying entities.
Researchers at Scripps Research Institute find Runx3 protein enables killer T cells to accumulate in solid tumors, potentially improving cancer immunotherapy strategies. Enhancing Runx3 activity delays tumor growth and prolongs survival in mouse melanoma models.
Researchers found that SIRT1 stabilizes a mechanism preventing immune cell toxic effects, but its loss accelerates glycolysis and cytokine production. This understanding led to potential new drug targets to strengthen or weaken SIRT1, potentially countering age-related diseases.
A research team at GW University will study the body's natural defenses against HIV, focusing on killer T-cells that can kill infected cells. The goal is to boost these immune cells to eliminate viral reservoirs and provide guidance for further therapeutic strategy development.
Researchers at UMass Amherst have identified a microRNA molecule called let-7 that serves as a molecular control hub to direct the function of cytotoxic T lymphocytes, enabling them to kill tumors and pathogens. When let-7 levels are low or absent, T cells can become super killers, potentially enhancing immune responses.
Researchers have identified a genetic variation that increases the risk of severe flu symptoms in patients. The variant, known as rs34481144, is linked to reduced killer T cell function and lower levels of the protective IFITM3 protein, suggesting a potential genetic marker for flu risk.
Researchers at La Jolla Institute for Allergy and Immunology identify tissue-resident memory T cells as an important distinguishing factor between cancer patients whose immune system mounts an effective anti-tumor response. The study found that patients with a high density of these cells in tumor tissue survived significantly longer.
Scientists have identified antiviral T cells that can access HIV's germinal center hideouts using the CXCR5 molecule. These cells have stem cell-like properties and can infiltrate sites of ongoing viral replication, providing a potential target for therapeutic vaccines and HIV suppression.
Immune system cells, specifically cytotoxic T cells, attack blood vessels in the brain, causing fatal swelling and damage. Inhibiting these cells with antibodies prevents the condition, suggesting a potential new approach to treating cerebral malaria.
A small molecule can turn short-lived T-cells into long-lived, renewable cells that destroy tumour cells. Researchers have identified a way to increase the life-span of these T-cells, overcoming a key hurdle in immunotherapy.
Scientists have discovered specialized killer T cells that can migrate into lymphoid tissue to control hidden infections like HIV and glandular fever. This breakthrough discovery could lead to new therapies to treat chronic infections.
Researchers at the University of Oxford have made breakthrough in treating HIV by targeting its dormant cells. A novel protein called ImmTAV has been shown to effectively kill latently infected cells in laboratory conditions.
A recent study published in The Journal of Clinical Investigation found that certain bacteria can activate killer T-cells, which destroy insulin-producing cells and lead to type 1 diabetes. This discovery sheds light on the potential external factors contributing to the disease's development.
Researchers have found that MHC class II molecules on graft endothelial cells activate CD4+ effector memory T cells, which then promote the development of graft-targeting CD8+ cytotoxic T cells. This interaction can be blocked to limit acute rejection in organ transplants.
Researchers develop 'kick and kill' strategy using Dual-Affinity Re-Targeting molecules to target HIV-infected cells and killer T cells. The study shows that the molecules can induce killing of infected cells and reduce detectable HIV expression in blood cells.
Researchers at Osaka University have discovered a new role for p62 in the immune response to Toxoplasma gondii, paving the way for the development of an inactivated vaccine. The study found that p62 plays a crucial role in activating killer T cells in infected cells stimulated by interferon-γ.
A new bi-specific antibody, DART, has been developed to bind HIV-infected cells to the immune system's killer T cells, potentially clearing HIV infection. The molecule was engineered using HIV-targeting antibodies and showed early promise in pre-clinical models.
Scientists discovered that helper T cells boost killer cell reproduction and provide memory, enabling them to remember previous infections. This understanding could lead to the development of new vaccines that activate killer cells with harmless fragments of disease pathogens.
Researchers at the University of Melbourne have captured images of immune cells responding to herpes simplex virus using state-of-the-art microscopy. The study reveals the dynamic choreography between killer T cells, helper T cells and dendritic cells as they work together to defeat an infection.
Researchers found that regulatory T cells suppress killer T cells through a protein on their surface, enabling the immune system to remember past pathogens. This discovery could lead to faster-acting vaccines and improved immunity to diseases like cancer.
Researchers found that EBV-infected B cells evade immune system using the viral protein LMP2A. The protein interferes with recognition by CD8+ T cells, allowing infected cells to escape detection and elimination.
A new study found that younger, unrelated donors with high T cell counts, particularly CD8 cells, resulted in significantly reduced disease relapse and improved survival rates for older patients. Screening for donor T cell characteristics may help optimize donor selection for these transplants.
A new Stanford University School of Medicine study found that vast numbers of self-reactive immune cells remain in circulation well into adulthood, challenging the long-held belief that they are weeded out early in life. This suggests that adults may be more susceptible to autoimmune disease than previously thought.
Researchers from the University of Cambridge captured the process of cytotoxic T cells destroying cancer cells using state-of-the-art imaging techniques. The study reveals the remarkable precision and efficiency with which these cells patrol our bodies, identifying and eliminating virally infected and cancerous cells.
A team of Yale and Johns Hopkins researchers identified a strategy to stimulate killer T cells to target and destroy infected cells harboring dormant viruses. The study suggests that directing CTL responses to unaltered pieces of virus may be the future direction for developing a therapeutic vaccine to clear HIV.
Researchers discover that HIV's ability to mutate beyond recognition evades the immune system. A new study finds that training killer T cells to recognize unaltered viral protein segments can reawaken the natural killer instinct, killing 61% of HIV-infected cells.
Scientists successfully killed HIV-infected cells using a new technique that boosts killer T-cell response. The method could be used as part of an HIV cure strategy by awakening latent immune cells and generating an immune response.
Research suggests that HDAC inhibitors used to flush out HIV from infected cells may also suppress the immune system's ability to target and eliminate these cells. This finding has significant implications for the development of effective HIV eradication strategies.
Researchers at the Salk Institute have identified a key control mechanism on regulatory T cells that maintain immune system balance. Removing a specific genetic sequence in Foxp3 destabilizes these cells, leading to autoimmune disease in animal models.
A new large animal model was developed to study immune responses to H. pylori, a leading cause of peptic ulcers. The pig model showed an increase in pro-inflammatory CD4+ T helper cells and cytotoxic T cells, mirroring recent human clinical studies.
Scientists at Walter and Eliza Hall Institute identify IRF4 protein as key regulator of elite killer T cells, which recognize and fight infections. Enhanced IRF4 production boosts immune response against HIV and other chronic infections.
Researchers have discovered that mature CD4+ helper T lymphocytes can reprogram into killer-like CD8+ T lymphocytes, gaining killing functions. This unexpected plasticity expands the functional capabilities of CD4+ T cells, suggesting they may play a direct protective role in immune responses.
The study found that CD4 helper T cells can transform into killer cells by overcoming a suppression mechanism triggered by a transcription factor. This transformation enables the helper cells to take on the role of killer cells in mounting an immune attack against viruses, cancerous tumors, and other damaged or infected cells.
Researchers discovered that Tip-dendritic cells activate naive CD8+ T cells to recognize myelin protein, leading to autoimmune reactivity. This finding sheds light on the complex role of CD8+ T cells in multiple sclerosis pathology.
Researchers from RIKEN have successfully created cancer-specific, immune system cells called killer T lymphocytes from induced pluripotent stem cells. These cells can potentially serve as a cancer therapy in the future, overcoming limitations of lab-produced killer T cells with short lifespan.
A recent study suggests that CD4+ T helper cells play a crucial role in controlling hepatitis A virus infection by suppressing virus growth without causing liver damage. This finding may explain why some patients relapse after clearing the infection.
Researchers found that individuals with HIV who can control viral replication have killer T cells with effective T cell receptors, which recognize and kill infected cells. The study suggests that the particular sequence of the protein affects the ability to control infection.
Scientists at UCSF used a pioneering imaging technique to study the interaction between breast cancer and the immune system in mice. They found that activated immune cells are headed off at the pass by healthy cells forming a 'thin red line' around tumors.
Researchers have discovered that immune cells in the brain use a two-tier approach to combat infections, sending signals to neighboring cells while focusing their attack on infected cells. This finding may help researchers develop new treatments for brain tumors and autoimmune diseases.
Researchers find that loss of STAT1 protein leads to increased breast cancer development in mice, as the immune system loses ability to control tumors. This discovery suggests that STAT1 may play a crucial role in preventing unwanted cell division and tumor growth.
Researchers developed a novel technique to turn immune system killer T cells into more effective weapons by delivering DNA into instructor cells. The method proved effective in jumpstarting defective immune systems in immuno-compromised mice and human killer T cells, paving the way for potential cancer therapy.
Researchers found that cytotoxic T lymphocytes are triggered by damage-associated molecular patterns (DAMPs) released after cell death, which signals a strong immune response. The presence of interleukin 33 (IL-33) amplifies this response, holding promise for developing new vaccines against infectious diseases and cancer.
A new MIT study suggests that electric vehicles can cost 9 to 12 percent less to operate than diesel engines for urban deliveries, leading to potential savings of $900 to $1,400 per truck per year. The study also explores the viability of vehicle-to-grid systems, which could provide additional revenue streams through power services.